Company Overview
Company Type: Public Company
Website: www.cipherpharma.com
Number of Employees: 5
Ticker: CPH (TSX)
Year Founded: 2000


Business Description
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome. The companyâ€™s licensed products comprise Absorica, an oral retinoid indicated for the treatment of severe recalcitrant nodular acne; Lipofe indicated as adjunctive therapy to diet to reduce triglycerides in adult patients with severe hypertriglyceridemia; and Conzip, an opioid agonist indicated for the management of moderate to moderately severe chronic pain in adults. Its pipeline products include CF-101 for severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical formulation of terbinafine for treatment of onychomycosis; and DTR-001, a tattoo removal cream. Cipher Pharmaceuticals Inc. was founded in 2000 and is headquartered in Mississauga, Canada.

Financial Information (Currency: CAD, in mm) 
Total Revenue
27.2
Market Capitalization
108.9
TEV/Total Revenue
2.2x
EBITDA
15.0
Total Enterprise Value
61.3
TEV/EBITDA
3.9x
EBIT
13.3
Cash & ST Invst.
49.7
P/Diluted EPS Before Extra
2.9x
Net Income
38.3
Total Debt
0.5
Price/Tang BV
1.5x
Capital Expenditure
(0.1)
Total Assets
110.3
Total Debt/EBITDA
0.0x
Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Oct-05-2023


Estimates Snapshot (Current Fiscal Year End: Dec-31-2023 | Currency: CAD)
Periodic Estimates
Current FQ
Current FQ+1
Current FY
Current FY+1
NTM
EPS (GAAP)
0.09
0.09
0.50
0.40
0.45
Revenue (mm)
7.03
7.16
27.83
28.68
28.25
EBITDA (mm)
3.92
3.96
16.05
16.02
16.04

Forward Multiples (Current FY)

Price/Earnings
8.59x
TEV/REV
2.22x
TEV/EBITDA
3.85x
P/BV
1.11x

Non-Periodic Estimates

Recommendation
Buy (1.33)
Target Price
4.33
Potential Upside
(0.38)%


Key Professionals
Name
Title
Mull, Craig J.
Interim CEO & Chairman of the Board
Jacobs, Bryan 
Chief Financial Officer
Gajewczyk, Diane 
Vice President of Scientific & Medical Affairs
Presti, Emilio 
Director of Sales & Marketing

Key Board Members
Name
Title
Mull, Craig J.
Interim CEO & Chairman of the Board
Deeth, Douglas Norman
Independent Director
Walinski, Hubert 
Independent Director
Wolkin, Harold Morton
Lead Independent Director


Primary Industry Classification
Pharmaceuticals


Primary Office Location
5750 Explorer Drive Suite 404 | Mississauga, ON | L4W 0A9 | Canada
Phone: 905-602-5840   

Current and Pending Investors
Athyrium Capital Management, LP, NB Alternatives Advisers LLC

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 4.35
Market Cap (mm)
110.1
Open
 4.35
Shares Out. (mm)
25.3
Previous Close
 4.35
Float %
56.6%
Change on Day
0.03
Shares Sold Short (mm)
-
Change % on Day
0.7%
Dividend Yield %
-
Day High/Low
 4.35/ 4.25
Diluted EPS Excl. Extra Items
1.50
52 wk High/Low
 4.58/ 2.85
P/Diluted EPS Before Extra
2.89x
Volume (mm)
0.0069
Avg 3M Dly Vlm (mm)
0.02
Beta 5Y
0.89


 
Delayed Quote** | Last Updated on Oct-06-2023 12:00 AM (GMT-5)
TSX:CPH - Common Stock


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Cardiome Pharma Corp.
Cardiome Pharma Corp. operates as a specialty pharmaceutical company.  Its commercial and pipeline hospital products administered in the acute care setting includes Brinavess (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm; Aggrastat (tirofiban hydrochloride) for the reduction of thrombotic cardiovascular events in patients with acute coronary syndrome; Xydalba (dalbavancin hydrochloride) for the treatment of acute bacterial skin and skin structure infections; and Trevyent, a drug device combination that delivers treprostinil for pulmonary arterial hypertension. The company is based in Mississauga, Canada. As of May 14, 2018, Cardiome Pharma Corp. was acquired by Cipher Pharmaceuticals Inc.

United States and Canada
Pharmaceuticals
-
-
-
Worldwide Rights to Investigational Tattoo Removal Cream
As of April 30, 2016, Worldwide Rights to Investigational Tattoo Removal Cream were acquired by Cipher Pharmaceuticals Inc. Worldwide Rights to Investigational Tattoo Removal Cream comprises development and commercialization of an investigational tattoo removal cream. The asset is located in the United States.

United States and Canada
Personal Care Products
-
-
-
Astion Pharma, Worldwide Rights to Dermadexin, Pruridexin And ASF-1096
As of February 26, 2015, Worldwide Rights to Dermadexin, Pruridexin And ASF-1096 of Astion Pharma were acquired by Cipher Pharmaceuticals Inc. Worldwide Rights to Worldwide Rights to Dermadexin, Pruridexin And ASF-1096 of Astion Pharma manufactures dermatological products.

Europe
Pharmaceuticals
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Sep-05-2023
-
Buyback
Target
Cipher Pharmaceuticals Inc. (TSX:CPH)


4.41
Sep-19-2022
-
Buyback
Target
Cipher Pharmaceuticals Inc. (TSX:CPH)


-
Sep-08-2021
Sep-09-2022
Buyback
Target
Cipher Pharmaceuticals Inc. (TSX:CPH)


2.62
Aug-12-2020
-
Buyback
Target
Cipher Pharmaceuticals Inc. (TSX:CPH)


0.72
Mar-20-2018
May-14-2018
Merger/Acquisition
Buyer
Cardiome Pharma Corp.
Cipher Pharmaceuticals Inc. (TSX:CPH)
Cardiome Pharma Corp. (nka:Correvio Pharma Corp.)
19.49
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-05-2023
Buyback Transaction Announcements
Cipher Pharmaceuticals Inc. (TSX:CPH) announces an Equity Buyback for CAD 6 million worth of its shares.
Sep-05-2023
Buyback Transaction Announcements
Cipher Pharmaceuticals Inc.authorizes a Buyback Plan.
Aug-11-2023
Earnings Calls
Cipher Pharmaceuticals Inc., Q2 2023 Earnings Call, Aug 11, 2023
Aug-11-2023
Seeking Acquisitions/Investments
Cipher Pharmaceuticals Seeks M&A
Aug-10-2023
Buyback Tranche Update
Tranche Update on Cipher Pharmaceuticals Inc. (TSX:CPH)'s Equity Buyback Plan announced on September 19, 2022.

Competitors
Acerus Pharmaceuticals Corporation, HLS Therapeutics Inc. (TSX:HLS), Pharmascience Inc.

M&A Advisors
Cooley LLP, Morgan, Lewis & Bockius LLP, PricewaterhouseCoopers LLP, Canada, Wildeboer Dellelce LLP


Advisors
Most Recent Auditor
Ernst & Young LLP
M&A Advisors
Cooley LLP, Morgan, Lewis & Bockius LLP, PricewaterhouseCoopers LLP, Canada, Wildeboer Dellelce LLP
Private Placement Advisors
Clarus Securities Inc., National Bank Financial, Inc., Piper Sandler Companies (NYSE:PIPR), RF Securities Clearing LP
Public Offering Advisors
Goodmans LLP, PricewaterhouseCoopers LLP, Canada


Most Recent Auditor
Ernst & Young LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
S&P Global Compustat

Oct 05, 2023 03:36 AM
CPH
Cipher Pharmaceuticals Inc 2023_10_05
Reports
15
ValuEngine, Inc.

Oct 02, 2023 06:06 AM
CPH
ValuEngine - Toronto Quantitative Stock Report for CPH
Reports
5
The Economy Matters

Oct 02, 2023 02:13 AM
CPH
The Economy Matters
Reports
8
GlobalData

Sep 26, 2023 05:10 AM
CPH
Cipher Pharmaceuticals Inc (CPHR.NASD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
41
Jefferson Research & Management

Sep 15, 2023 12:54 PM
CPH
Jefferson Financial - Cipher Pharmaceuticals Inc.
Reports
11
GlobalData

Sep 12, 2023 04:00 AM
CPH
Cipher Pharmaceuticals Inc (CPH.TSE) - Financial Analysis Review
Reports
406
Jefferson Research & Management

Sep 08, 2023 12:59 PM
CPH
Jefferson Financial - Cipher Pharmaceuticals Inc.
Reports
11
S&P Global Compustat

Sep 07, 2023 03:23 AM
CPH
Cipher Pharmaceuticals Inc 2023_09_07
Reports
15
Jefferson Research & Management

Sep 01, 2023 12:56 PM
CPH
Jefferson Financial - Cipher Pharmaceuticals Inc.
Reports
11
Jefferson Research & Management

Aug 25, 2023 12:43 PM
CPH
Jefferson Financial - Cipher Pharmaceuticals Inc.
Reports
11


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Mull F.R.C.P. (C), M.D., John D.

9,566,150

37.80

41.3

May-10-2023


Mull, Craig J.

719,135

2.84

3.1

Jun-21-2023


Wolkin B.A, CFA, ICD, M.Econ, Harold Morton

359,015

1.42

1.6

Sep-18-2023


Deboeck, Arthur M.

251,540

0.99

1.1

Mar-29-2023


Huber Capital Management LLC

224,700

0.89

1.0

Jul-31-2023


Gajewczyk, Diane 

84,036

0.33

0.4

Mar-29-2023


Jacobs, Bryan 

5,000

0.02

0.0

Mar-16-2023


Steiner CA, CPA, MBA, MSc, Cathy Robin

5,000

0.02

0.0

Mar-29-2023


Acadian Asset Management LLC

2,369

0.01

0.0

Jul-31-2023


Godin, Christian

0

0.00

0.0

Jun-21-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Mull F.R.C.P. (C), M.D., John D.
9,566,150
9,566,150
Mull, Craig J.
719,135
122,049
Huber Capital Management LLC
224,700
113,400
Wolkin B.A, CFA, ICD, M.Econ, Harold Morton
359,015
3,688

Top Sellers
Sellers
Common Stock Equivalent Held
Change
Godin, Christian
0
(91,710)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
A-101, Actikerall, Aggrastat, ASF-1096, Beteflam, Bionect Foam, Brinavess, CF-101 (Future), Distribution of CIP-FENOFIBRATE, Distribution of CIP-ISOTRETINOIN, Distribution of CIP-TRAMADOL ER, DTR-001 (Future), Durela, Epuris, Licensing of Absorica, Licensing of ASF-1096, Licensing of CF101, Licensing of Conzip, Licensing of Lipofen, Lipofen, MOB-015 (Future), Nanolipolee-007, Nuvail, Ozanex, Sitavig, Trevyent, Vaniqa, Xydalba


Upcoming Events
Date/Time
Type
Nov-10-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Oct-03-2023
-
Cipher Pharmaceuticals Inc. (TSX:CPH)
SEDAR
News Releases
40 KB
Sep-08-2023
-
Cipher Pharmaceuticals Inc. (TSX:CPH)
SEDAR
Material Change Report
44 KB
Sep-05-2023
-
Cipher Pharmaceuticals Inc. (TSX:CPH)
SEDAR
News Releases
44 KB
Aug-14-2023
Jun-30-2023
Cipher Pharmaceuticals Inc. (TSX:CPH)
Company Website
Interim Report
2 MB
Aug-10-2023
-
Cipher Pharmaceuticals Inc. (TSX:CPH)
SEDAR
News Releases
244 KB
Aug-10-2023
Jun-30-2023
Cipher Pharmaceuticals Inc. (TSX:CPH)
SEDAR
Interim Financial Statements
376 KB
Jul-05-2023
-
Cipher Pharmaceuticals Inc. (TSX:CPH)
SEDAR
News Releases
45 KB
Jun-22-2023
-
Cipher Pharmaceuticals Inc. (TSX:CPH)
SEDAR
Management Proxy Materials
121 KB
Jun-21-2023
-
Cipher Pharmaceuticals Inc. (TSX:CPH)
SEDAR
News Releases
26 KB
May-30-2023
-
Cipher Pharmaceuticals Inc. (TSX:CPH)
SEDAR
Management Proxy Materials
170 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Wolkin B.A, CFA, ICD, M.Econ, Harold Morton (Lead Independent Director)
Sep-18-2023
Common Shares
1,026
4,680
Acquisition Under Employee Benefit Plan
0.29
Multiple
Wolkin B.A, CFA, ICD, M.Econ, Harold Morton (Lead Independent Director)
Aug-15-2023
Common Shares
1,330
4,684
Acquisition Under Employee Benefit Plan
0.37
Multiple
Wolkin B.A, CFA, ICD, M.Econ, Harold Morton (Lead Independent Director)
Jul-14-2023
Common Shares
1,332
4,812
Acquisition Under Employee Benefit Plan
0.37
Multiple
Wolkin B.A, CFA, ICD, M.Econ, Harold Morton (Lead Independent Director)
Jun-14-2023
Common Shares
1,207
4,722
Acquisition Under Employee Benefit Plan
0.34
Multiple
Wolkin B.A, CFA, ICD, M.Econ, Harold Morton (Lead Independent Director)
May-15-2023
Common Shares
1,562
5,334
Acquisition Under Employee Benefit Plan
0.44
Multiple
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Mull, Craig J.
Interim CEO & Chairman of the Board
905-602-5840
-

Deeth, Douglas Norman
Independent Director
905-602-5840
-

Walinski, Hubert 
Independent Director
905-602-5840
-

Wolkin, Harold Morton
Lead Independent Director
905-602-5840
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Mull, Craig J.
Interim CEO & Chairman of the Board
905-602-5840
-

Jacobs, Bryan 
Chief Financial Officer
905-602-5840
-

Gajewczyk, Diane 
Vice President of Scientific & Medical Affairs
905-602-5840
-

Presti, Emilio 
Director of Sales & Marketing
905-602-5840
-

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENTâ€™S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligenceâ€™s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
